Abstract
Introduction: Inflammation plays a crucial role in cancers, and the advanced lung cancer inflammation index (ALI) is considered to be a potential factor reflecting systemic inflammation. Objectives: This work aimed to explore the prognostic value of the ALI in metastatic non–small cell lung cancer (NSCLC) and classify patients according to risk and prognosis. Methods: We screened 318 patients who were diagnosed with stage IV NSCLC in Hubei Cancer Hospital from July 2012 to December 2013. The formula for ALI is body mass index (BMI, kg/m2) × serum albumin (Alb, g/dl)/neutrophil–lymphocyte ratio (NLR). Categorical variables were analyzed by the chi-square test or Fisher’s exact test. The overall survival (OS) rates were analyzed by the Kaplan–Meier method and plotted with the R language. A multivariate Cox proportional hazard model was used to analyze the relationship between ALI and OS. Results: According to the optimal cut-off value determined by X-tile software, patients were divided into two groups (the ALI <32.6 and ALI ≥32.6 groups), and the median OS times were 19.23 and 39.97 months, respectively (p < 0.01). A multivariable Cox regression model confirmed that ALI and chemotherapy were independent prognostic factors for OS in patients with NSCLC. OS in the high ALI group was better than that in the low ALI group (HR: 1.39; 95% CI: 1.03–1.89; p = 0.03). Conclusions: Patients with a low ALI tend to have lower OS among those with metastatic NSCLC, and the ALI can serve as an effective prognostic factor for NSCLC patients.
Highlights
Inflammation plays a crucial role in cancers, and the advanced lung cancer inflammation index (ALI) is considered to be a potential factor reflecting systemic inflammation
Our study aims to evaluate the prognostic value of ALI in patients with metastatic non–small cell lung cancer (NSCLC)
The results indicated that gender (p 0.045) and lactate dehydrogenase (LDH) (p < 0.001) were significantly associated with ALI
Summary
Inflammation plays a crucial role in cancers, and the advanced lung cancer inflammation index (ALI) is considered to be a potential factor reflecting systemic inflammation. It has been confirmed that some demographic characteristics are of great value in predicting the survival time of NSCLC; these include sex, age (Wang et al, 2019), chronic obstructive pulmonary disease (COPD) status (Loganathan et al, 2006; Ytterstad et al, 2016), and smoking status (de Groot and Munden, 2012) Various inflammatory factors, such as the Glasgow prognostic score (GPS) (Sandfeld-Paulsen et al, 2019; Imai et al, 2021), systemic immune-inflammation index (SII) (Tong et al, 2017; Zheng et al, 2021), NLR (Diem et al, 2017; Bongiovanni et al, 2021), and Aarhus composite biomarker score (ACBS) (Sandfeld-Paulsen et al, 2019), have been validated as prognostic markers in lung cancer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
